(DNTH)

Reporting relationship: Director
Issuer ticker: DNTH
Reported as of: 19 Aug 2026
Net transaction value: -$326,554
SEC form: 4
Accepted by SEC: 19 Aug 2026, 18:02:39 UTC
Prior SEC filing: 11 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Veness, as attorney-in-fact for Simon Read

Key filing fact

Simon Read filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 19 Aug 2026.

Key facts

This page summarizes Simon Read's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Aug 2026, 18:02.

Change

Previous filing in this sequence was filed on 11 Aug 2026.
Current net transaction value: -$326,554.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001688199 Primary reporting owner

Read Simon

Relationship: Director
Address: C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK
Signature: /s/ Adam Veness, as attorney-in-fact for Simon Read
Signature date: 19 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNTH transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,778
Change %
Price: $18.36^*
Shares after: 2,778
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F1

DNTH transaction

Common Stock

Sale

Transaction value: $326,554
Shares: -2,778
Change %: -100%
Price: $117.55
Shares after: 0
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNTH transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -2,778
Change %: -13%
Price: $0.000000^*
Shares after: 19,445
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,778
Exercise price: $18.36
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.

Footnote F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date.